Thank you for your patience while we transitioned to our upgraded systems. We continue to work through the backlog of orders, demographic changes, and other requests created during the downtime. Our priority is to resolve the backlog as quickly as possible. We appreciate your understanding and continued support.
Please log in to determine if you are eligible to purchase PT Programs.
HLA DISEASE ASSOCIATION-DRUG RISK - DADR2
DADR2
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Analyte
Challenges per Shipment
Number of Shipments
HLA-A*29:01
3
Two shipments per year
HLA-A*29:02
3
HLA-DQA1*04:01
3
HLA-DQA1*05:01
3
HLA-DQB1*03:02
3
HLA-DQB1*06:02
3
HLA-DRB1*03:01
3
HLA-DRB1*03:02
3
HLA-DRB1*04:02
3
HLA-DRB1*04:03
3
HLA-DRB1*04:06
3
HLA-DRB1*08:02
3
HLA-DRB1*08:04
3
HLA-DRB1*14:04
3
HLA-DRB1*14:05
3
HLA-DRB1*14:08
3
HLA-DRB1*15:01
3
HLA-DRB1*15:02
3
HLA-DQA1*02
3
HLA-DQA1*03
3
HLA-DQA1*05
3
HLA-DQB1*02:01
3
HLA-DQB1*02:02
3
Additional Information
This program will challenge the laboratory to accurately identify the presence or absence
of alleles associated with a variety of disease states (listed below) and/or the adverse
reactions to specific drugs.
Celiac disease
Narcolepsy
Pemphigus Vulgaris
Psoriasis
Antiglomerular basement membrane disease
Birdshot retinochoroidopathy
Idiopathic myopathy
Program Information
Three 0.1‑mL specimens, each containing 200 µg/mL of human DNA in media
Help